Impact of donor infections on outcome of orthotopic liver transplantation
Open Access
- 1 May 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 9 (5) , 451-462
- https://doi.org/10.1053/jlts.2003.50094
Abstract
Infection occurs when microbial agents enter the host, either through airborne transmission or by direct contact of a substance carrying the infectious agent with the host. Human body fluids, solid organs, or other tissues often are ideal vectors to support microbial agents and can transmit infections efficiently from donor to recipient. In the case of blood transfusion and tissue transplantation, the main consequence of such a transmission is infection of the recipient. However, in the case of solid-organ transplantation, and particularly for liver transplantation, donor infections are not only transmitted to the recipient, the donor infection also may affect the donated liver’s preservability and subsequent function in the recipient irrespective of the systemic consequences of the infection. In addition, solid organ recipients of infected organs are less able to respond to the infectious agent because of their immunosuppressive treatment. Thus, transmission of infections from organ donor to liver recipient represents serious potential risks that must be weighed against a candidate’s mortality risk without the transplant. However, the ever-increasing gap between the number of donors and those waiting for liver grafts makes consideration of every potential donor, regardless of the infection status, essential to minimize waiting list mortality. In this review, we will focus on assessing the risk of transmission of bacterial, fungal, viral, and parasitic infectious agents from cadaveric liver donors to recipients and the effect such a transmission has on liver function, morbidity, and mortality. We will also discuss risk-benefit deliberations for using organs from infected donors for certain types of recipients. These issues are critically important to maximize the use of donated organs but also minimize recipient morbidity and graft dysfunction.Keywords
This publication has 92 references indexed in Scilit:
- Clinical Significance of Donor‐Unrecognized Bacteremia in the Outcome of Solid‐Organ Transplant RecipientsClinical Infectious Diseases, 2001
- Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapyLiver Transplantation, 2001
- Epidemiology of hepatitis CHepatology, 1997
- RISKS OF TRANSPLANTING KIDNEYS FROM HEPATITIS B SURFACE ANTIGEN-NEGATIVE, HEPATITIS B CORE ANTIBODY-POSITIVE DONORS1,2Transplantation, 1997
- De novo and apparent de novo hepatitis B virus infection after liver transplantationJournal of Hepatology, 1997
- Transmission of donor Epstein--Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipientsJournal of General Virology, 1996
- Transmission of Disseminated Histoplasmosis via Cadaveric Renal Transplantation: Case ReportClinical Infectious Diseases, 1992
- SYMPTOMATIC CYTOMEGALOVIRUS INFECTION IN SEROPOSITIVE KIDNEY RECIPIENTS: REINFECTION WITH DONOR VIRUS RATHER THAN REACTIVATION OF RECIPIENT VIRUSThe Lancet, 1988
- Acquisition of Donor Strains of Cytomegalovirus by Renal-Transplant RecipientsNew England Journal of Medicine, 1986
- HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITYThe Lancet, 1986